PCSK9-IN-1 is primarily used in research focused on cardiovascular diseases. It acts as an inhibitor of PCSK9, a protein that plays a key role in cholesterol metabolism. By inhibiting PCSK9, this compound helps increase the uptake of low-density lipoprotein (LDL) cholesterol by the liver, thereby reducing LDL levels in the bloodstream. This mechanism makes it a potential candidate for developing treatments for hypercholesterolemia and related conditions such as atherosclerosis. Researchers utilize PCSK9-IN-1 to study its efficacy and safety profile in preclinical models, aiming to pave the way for novel therapeutic interventions in managing high cholesterol and preventing cardiovascular events.